Long-term survival data further support nivolumab plus ipilimumab as first-line standard of care for patients with inoperable liver cancer.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/immunotherapy-duo-shows-sustained-benefit-liver-cancer-2026a100024r?src=rss
Author :
Publish date : 2026-01-22 10:57:00
Copyright for syndicated content belongs to the linked Source.
